MedWatch

Bioporto scores agreement with Roche and eyes profit

Last week, Bioporto disclosed a new global distribution agreement with Roche. The CEO calls the news “amazing” and spots a chance to generate income after years of deficit.

Foto: PR

Danish in-vitro diagnostics company Bioporto, that develops biomarkers, has signed a distribution agreement with Swiss drug group Roche. The agreement allows Roche to use Bioporto’s NGAL test for its analyzers.

This is according to a company announcement from Bioporto.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier